Afatinib in combination with cisplatin and 5-fluorouracil (5-FU) as first line treatment in inoperable gastric and gastro-esophageal junction (GEJ) cancer: A phase II study by the Hellenic Cooperative Oncology Group

被引：0
|
作者：
Makatsoris, T. [1 ]
Samantas, E. [1 ]
Manousou, K. [1 ]
Karavasilis, V. [1 ]
Aravantinos, G. [1 ]
Tryfonopoulos, D. [1 ]
Psyrri, A. [1 ]
Pectasides, D. G. [1 ]
Pazarli, E. [1 ]
Petraki, C. [1 ]
Tsipoura, A. [1 ]
Kaklamanos, I. G. [1 ]
Fountzilas, G. [1 ]
Pentheroudakis, G. [1 ]
机构：
[1] HeCOG, Data Off, Athens, Greece
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
677P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study
    Zarkavelis, George
    Samantas, Epaminontas
    Koliou, Georgia-Angeliki
    Papadopoulou, Kyriaki
    Mauri, Davide
    Aravantinos, Gerasimos
    Batistatou, Anna
    Pazarli, Elissavet
    Tryfonopoulos, Dimitrios
    Tsipoura, Anna
    Bobos, Mattheos
    Psyrri, Amanda
    Makatsoris, Thomas
    Petraki, Constantina
    Pectasides, Dimitrios
    Fountzilas, George
    Pentheroudakis, George
    ACTA ONCOLOGICA, 2021, 60 (06) : 785 - 793
  • [2] Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group
    Kentepozidis, Nikolaos
    Economopoulou, Panagiota
    Liontos, Michael
    Kotsakis, Athanasios
    Boukovinas, Ioannis
    Vardakis, Nikolaos
    Kontopodis, Emmanouil
    Prinarakis, Efthimios
    Skaltsi, Teressa
    Souglakos, John
    Georgoulias, Vassilis
    ANNALS OF GASTROENTEROLOGY, 2018, 31 (06): : 698 - +
  • [3] Phase II study of gemcitabine, cisplatin, folinic acid (FA) and infusional 5-fluorouracil (5-FU) in patients with inoperable esophageal cancer (IEC).
    Hilbig, A
    Stieler, J
    Pelzer, U
    Okenga, J
    Hintze, R
    Roll, L
    Gövercin, M
    Arning, M
    Riess, H
    Oettle, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 372S - 372S
  • [4] The efficacy and safety of combination chemotherapy with paclitaxel, 5-fluorouracil (5-FU) and cisplatin for advanced gastric carcinoma: A phase II study
    Kim, S.
    Lim, H.
    Lee, H.
    Yuh, Y.
    ANNALS OF ONCOLOGY, 2007, 18 : VII54 - VII55
  • [5] PHASE 2 STUDY OF TELATINIB IN COMBINATION WITH CAPECITABINE AND CISPLATIN AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED CANCER OF THE STOMACH OR GASTRO-ESOPHAGEAL JUNCTION (GEJ)
    Alsina, M.
    Ajani, J. A.
    Ko, A. H.
    Garcia De Paredes, M. L.
    Rivera, F.
    Schwartzberg, L.
    Phan, A. T.
    Whiteside, M.
    Kunkel, L. A.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 229 - 229
  • [6] PHASE I-II STUDY OF THE COMBINATION OF 5-FU, DOXORUBICIN, MITOMYCIN, AND SEMUSTINE (FAMME) IN THE TREATMENT OF ADENOCARCINOMA OF THE STOMACH, GASTRO-ESOPHAGEAL JUNCTION, AND PANCREAS
    KARLIN, DA
    STROEHLEIN, JR
    BENNETTS, RW
    JONES, RD
    HEIFETZ, LJ
    MAHAL, PS
    CANCER TREATMENT REPORTS, 1982, 66 (08): : 1613 - 1617
  • [7] Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma
    Fotios Loupakis
    Gianluca Masi
    Lorenzo Fornaro
    Enrico Vasile
    Giacomo Allegrini
    Eloise Fontana
    Cristina Granetto
    Lisa Salvatore
    Lucia Mentuccia
    Michele Andreuccetti
    Enrico Cortesi
    Marco Merlano
    Stefano Cascinu
    Alfredo Falcone
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 559 - 566
  • [8] Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma
    Loupakis, Fotios
    Masi, Gianluca
    Fornaro, Lorenzo
    Vasile, Enrico
    Allegrini, Giacomo
    Fontana, Eloise
    Granetto, Cristina
    Salvatore, Lisa
    Mentuccia, Lucia
    Andreuccetti, Michele
    Cortesi, Enrico
    Merlano, Marco
    Cascinu, Stefano
    Falcone, Alfredo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (03) : 559 - 566
  • [9] PHASE II STUDY OF DOCETAXEL AND 5-FLUOROURACIL (5-FU) WITH CONCURRENT RADIOTHERAPY IN PATIENTS WITH ADVANCED ESOPHAGEAL CANCER
    Hihara, J.
    Hamai, Y.
    Emi, M.
    Aoki, Y.
    Miyata, Y.
    Okada, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 238 - 238
  • [10] A retrospective study of neoadjuvant DCF (docetaxel, cisplatin, 5-fluorouracil) for locally advanced gastric or gastro-esophageal junction adenocarcinoma (GC)
    Castellanos, Raquel
    Emani, Vinicius
    Bayraktar, Ulas Darda
    Portelance, Lorraine
    Montero, Alberto J.
    Lima, Calo Max S. Rocha
    Hosein, Peter Joel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
12345